Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBT Margin (2016 - 2026)

Anika Therapeutics has reported EBT Margin over the past 17 years, most recently at 16.28% for Q1 2026.

  • Quarterly EBT Margin fell 150.0% to 16.28% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.01% through Mar 2026, up 514.0% year-over-year, with the annual reading at 0.83% for FY2025, 423.0% up from the prior year.
  • EBT Margin was 16.28% for Q1 2026 at Anika Therapeutics, down from 35.97% in the prior quarter.
  • Over five years, EBT Margin peaked at 35.97% in Q4 2025 and troughed at 871.99% in Q4 2023.
  • The 5-year median for EBT Margin is 10.11% (2022), against an average of 85.02%.
  • Year-over-year, EBT Margin plummeted -41670bps in 2023 and then soared 86782bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 455.29% in 2022, then tumbled by -92bps to 871.99% in 2023, then soared by 100bps to 4.17% in 2024, then soared by 963bps to 35.97% in 2025, then crashed by -145bps to 16.28% in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EBT Margin are 16.28% (Q1 2026), 35.97% (Q4 2025), and 8.04% (Q3 2025).